gene

NAMPT

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about NAMPT: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

582Connections

7Hypotheses

8Analyses

50Outgoing

50Incoming

5Experiments

16Debates

Summary

NAMPT is a gene implicated in neurodegeneration research. Key relationships include: regulates, associated with, inhibits. Associated with ALS, Aging, Als. Connected to 221 entities in the SciDEX knowledge graph.

View on Wiki →

No AI portrait yet

🧬 Gene Info

Gene Symbol	NAMPT
Full Name	Nicotinamide Phosphoribosyltransferase
Aliases	Nicotinamide Phosphoribosyltransferase/Visfatin
Chromosome	7q22.3
Protein Type	Enzyme
Target Class	Enzyme
Function	Small molecule competitive inhibitors of NAD+ biosynthesis enzyme
Mechanism of Action	Small molecule competitive inhibitors of NAD+ biosynthesis enzyme
Druggability	Low (0.45)
Clinical Stage	Phase II
Molecular Weight	52 kDa
Pathways	Akt, Angiogenesis, Autophagy, Cerebrovascular, Cholesterol Metabolism
UniProt ID	A0A7P0TA73
NCBI Gene ID	10135
Ensembl ID	ENSG00000105835
OMIM	608064
GeneCards	NAMPT
Human Protein Atlas	NAMPT
Associated Diseases	aging, Als, Alzheimer
Known Drugs/Compounds	NAMPT positive allosteric modulators, nicotinamide
Interactions	Actin, AGING, AKT, AMPK, AND, APOE4
SciDEX Target	View Target Profile (8 clinical trials)
SciDEX Hypotheses	TREM2 R47H Variant-Driven Metabolic Dysfunction as Metabolic NAD+ Salvage Pathway Enhancement Through NAD+ Salvage Pathway Optimization
KG Connections	582 knowledge graph edges
Databases	GeneCards HPA STRING

🔮 Predicted Structure: NAMPT — AlphaFold A0A7P0TA73 Click to expand

AI-predicted structure from AlphaFold | Powered by Mol*

Wiki Pages (2)

Knowledge base pages for this entity

Canonical Page

NAMPT Gene

gene · 1368 words

→

NAMPT Protein

protein · 884 words

→

Pathway Diagram

graph TD
    NAMPT["NAMPT"] -->|"associated"| neurodegeneration["neurodegeneration"]
    NAMPT["NAMPT"] -->|"interacts"| CD38["CD38"]
    NAMPT["NAMPT"] -->|"interacts"| TLR4["TLR4"]
    NAMPT["NAMPT"] -->|"co discussed"| GPX4["GPX4"]
    NAMPT["NAMPT"] -->|"co discussed"| PLA2G6["PLA2G6"]
    NAMPT["NAMPT"] -->|"co discussed"| MMP2["MMP2"]
    CD38_1["CD38"] -->|"interacts"| NAMPT["NAMPT"]
    MMP9["MMP9"] -->|"co discussed"| NAMPT["NAMPT"]
    SLC7A11["SLC7A11"] -->|"co discussed"| NAMPT["NAMPT"]
    AQP4["AQP4"] -->|"co discussed"| NAMPT["NAMPT"]
    style NAMPT fill:#4a1a6b,stroke:#4fc3f7,stroke-width:2px,color:#e0e0e0

Outgoing (404)

Target	Relation	Type	Str
NAD+ depletion	causes	mechanism	0.95
NAD salvage pathway	involved_in	pathway	0.90
NAD+ salvage pathway	regulates	pathway	0.90
NAD+	activates	metabolite	0.90
NAD+	regulates	metabolite	0.90
NAD+ biosynthesis	regulates	pathway	0.90
neurodegenerative pathophysiology	causes	disease	0.90
Nad+ Biosynthesis	associated_with	pathway	0.90
SIRT1	activates	protein	0.89
Inflammatory Bowel Disease	upregulates	disease	0.85
NAD+ biosynthesis	catalyzes	pathway	0.80
Cancer	associated_with	disease	0.75
Als	associated_with	disease	0.75
NAD+ metabolism	participates_in	pathway	0.75
Neutrophilic Inflammation	involved_in	process	0.75
ferroptosis	participates_in	pathway	0.70
NAD+ restoration	regulates	phenotype	0.70
NAD+ restoration	causes	process	0.70
Mitochondrial Function	associated_with	pathway	0.70
Ms	regulates	disease	0.65
Stroke	contributes_to	disease	0.65
Leukemia	therapeutic_target	disease	0.65
Tumor	regulates	disease	0.65
Stroke	activates	disease	0.65
Cardiovascular	regulates	disease	0.65
Alzheimer	associated_with	disease	0.65
Tumor	associated_with	disease	0.65
Obesity	contributes_to	disease	0.65
Als	expressed_in	disease	0.65
Cancer	protects_against	disease	0.65
Cancer	activates	disease	0.65
Addiction	therapeutic_target	disease	0.65
Als	therapeutic_target	disease	0.65
Diabetes	contributes_to	disease	0.65
Atherosclerosis	regulates	disease	0.65
Alzheimer	therapeutic_target	disease	0.65
Aging	causes	disease	0.65
Obesity	therapeutic_target	disease	0.65
Cancer	therapeutic_target	disease	0.65
Neurodegeneration	causes	disease	0.65
Aging	therapeutic_target	disease	0.65
Als	causes	disease	0.65
Alzheimer	expressed_in	disease	0.65
Inflammation	associated_with	disease	0.65
Stroke	therapeutic_target	disease	0.65
ALS	associated_with	disease	0.65
Aging	associated_with	disease	0.65
Neurodegeneration	activates	disease	0.65
Stroke	regulates	disease	0.65
Ms	associated_with	disease	0.65

Incoming (178)

Source	Relation	Type	Str
AEP	degrades	unknown	0.95
NAD	associated_with	gene	0.90
h-var-159030513d	targets_gene	hypothesis	0.90
C/EBPβ	inhibits	unknown	0.90
h-cb833ed8	targets	hypothesis	0.90
NAMPT positive allosteric modulators	modulates	drug	0.80
CD38	associated_with	gene	0.80
nicotinamide	targets	drug	0.75
NMN supplementation	bypasses	intervention	0.70
APOE4	inhibits	gene	0.70
NAD	treats	gene	0.70
apoe4	inhibits	disease	0.70
DNA	associated_with	gene	0.70
CD38	interacts_with	gene	0.64
RB1	therapeutic_target	gene	0.60
AUTOPHAGY	regulates	gene	0.60
AMPK	regulates	gene	0.60
MITOPHAGY	regulates	gene	0.60
STROKE	activates	gene	0.60
DEMENTIA	expressed_in	gene	0.60
ALZHEIMER	expressed_in	gene	0.60
APP/PS1	inhibits	gene	0.60
ALZHEIMER	associated_with	gene	0.60
WNT	associated_with	gene	0.60
NEURODEGENERATIVE DISEASES	associated_with	gene	0.60
RNA	inhibits	gene	0.60
IMMUNE INFILTRATION	associated_with	gene	0.60
FEATURE DEGS	associated_with	gene	0.60
NADH	expressed_in	gene	0.60
NAD	accumulates_in	gene	0.60
CSF2	regulates	gene	0.60
AKT	regulates	gene	0.60
RPS6	therapeutic_target	gene	0.60
CXCR4	associated_with	gene	0.60
SIRT1	therapeutic_target	gene	0.60
NRF2	associated_with	gene	0.60
TNF	associated_with	gene	0.60
PTGS2	encodes	gene	0.60
ferroptosis	activates	pathway	0.60
ferroptosis	binds_to	pathway	0.60
ERK	regulates	gene	0.60
EPOR	regulates	gene	0.60
EPO	regulates	gene	0.60
CYTOKINES	contributes_to	gene	0.60
FOSL2	activates	gene	0.60
ROS	activates	gene	0.60
RNA	activates	gene	0.60
GSH	activates	gene	0.60
NEURODEGENERATION	causes	gene	0.60
ATP	regulates	gene	0.60

Targeting Hypotheses (7)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
TREM2 R47H Variant-Driven Metabolic Dysfunction as the Prima	0.862	neurodegeneration	Variant Annotation and Prioritization of
Metabolic NAD+ Salvage Pathway Enhancement Through NAMPT Ove	0.745	neurodegeneration	Epigenetic reprogramming in aging neuron
NAMPT-Centered NAD+ Restoration to Reverse Basal Forebrain C	0.616	neurodegeneration	Do β-amyloid plaques and neurofibrillary
NRF2-Mediated Metabolic Reprogramming: HBOT as Direct NAMPT/	0.602	neurodegeneration	What are the optimal oxygen pressure, du
NAMPT-SIRT1 Axis as Master Regulator of SASP-Dependent Compl	0.592	neurodegeneration	test

Combined NAMPT-Alectinib Targeting of SASP-Complement Cascad	0.549	neuroinflammation	How does Alectinib, a kinase inhibitor,
NAD+ Salvage Pathway Optimization	0.455	neurodegeneration	Which specific metabolic pathways in APO

Mentioning Analyses (8)

Scientific analyses that reference this entity

What mechanisms drive the self-amplifying vicious cycle linking oxidative stress

neurodegeneration | 2026-04-25 | 6 hypotheses Top: 0.760

Do β-amyloid plaques and neurofibrillary tangles cause or result from cholinergi

neurodegeneration | 2026-04-16 | 2 hypotheses Top: 0.616

Which specific metabolic pathways in APOE4+ microglia are most therapeutically t

neurodegeneration | 2026-04-08 | 7 hypotheses Top: 0.455

Senescent cell clearance as neurodegeneration therapy

neurodegeneration | 2026-04-04 | 7 hypotheses Top: 0.769

Which metabolic biomarkers can distinguish therapeutic response from disease pro

translational neuroscience | 2026-04-04 | 10 hypotheses Top: 0.829

Experiments (5)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Model	Status	Est. Cost
FK866 efficacy in IBD patient-derived lamina propria cells	clinical	Inflammatory bowel disease	0.950	Human IBD patient-derived LPMN	proposed	N/A
FK866 treatment in DSS-induced colitis mouse model	validation	Inflammatory bowel disease (co	0.900	DSS-induced colitis mice	proposed	N/A
NAD depletion effects on monocyte/macrophage differentiation	exploratory	Inflammatory bowel disease	0.900	Primary mouse and human monocy	proposed	N/A
FK866 in azoxymethane/DSS colitis-associated cancer model	validation	Colitis-associated cancer	0.850	AOM/DSS-treated mice	proposed	N/A
FK866 mechanism validation in Rag1-/- mice	validation	Inflammatory bowel disease	0.850	Rag1-/- mice with DSS-induced	proposed	N/A

Related Papers (7)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year
First-in-Human Phase I Study of KPT-9274, a First-in-Class Dual Inhibitor of PAK [PMID:41824279]	["Razak A", "Mahipal A", "Diamond JR", "	Target Oncol	2026
Enhancing TREM2 expression activates microglia and modestly mitigates tau pathol [PMID:40122810]	["Chen Kai", "Li Fuyao", "Zhang Shuwen",	Journal of neuroinflammation	2025
Enhancing TREM2 expression activates microglia and modestly mitigates tau pathol [PMID:40122810]	["Chen Kai", "Li Fuyao", "Zhang Shuwen",	Journal of neuroinflammation	2025
Neurodegeneration and Inflammation-An Interesting Interplay in Parkinson's Disea [PMID:33182554]	Marogianni C, Sokratous M, Dardiotis E,	International journal of molec	2020
Neurodegeneration and Inflammation-An Interesting Interplay in Parkinson's Disea [PMID:33182554]	Marogianni C, Sokratous M, Dardiotis E,	International journal of molec	2020
Multiple Sclerosis Pathology. [PMID:29358320]	Lassmann H	Cold Spring Harbor perspective	2018
Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic st [PMID:25709099]	["Sampath D", "Zabka TS", "Misner DL", "	Pharmacol Ther	2015

Debates (16)

Multi-agent debates referencing this entity

Extended debate: Metabolic Reprogramming to Reverse Senescence

closed · Rounds: 6 · Score: 0.95 · 2026-04-27

Hypothesis debate: Metabolic Reprogramming to Reverse Senescence

closed · Rounds: 4 · Score: 0.44 · 2026-04-27

Hypothesis debate: SASP-Mediated Complement Cascade Amplification

closed · Rounds: 4 · Score: 0.40 · 2026-04-27

Hypothesis debate: SASP Modulation Rather Than Cell Elimination

closed · Rounds: 4 · Score: 0.50 · 2026-04-26

Hypothesis debate: Metabolic Reprogramming to Reverse Senescence

closed · Rounds: 4 · Score: 0.50 · 2026-04-26

Hypothesis debate: Metabolic Reprogramming to Reverse Senescence

closed · Rounds: 4 · Score: 0.50 · 2026-04-26

What mechanisms drive the self-amplifying vicious cycle linking oxidative stress

closed · Rounds: 4 · Score: 0.84 · 2026-04-25

Should metabolic reprogramming via SIRT1/NAD+/PGC-1alpha axis be prioritized to

closed · Rounds: 4 · Score: 0.81 · 2026-04-23

The abstract explicitly questions whether AD's hallmark pathologies induce choli

closed · Rounds: 4 · Score: 0.95 · 2026-04-16

Investigate the therapeutic potential of clearing senescent cells (senolytics) t

closed · Rounds: 4 · Score: 0.75 · 2026-04-16

Related Research

Hypotheses and analyses mentioning NAMPT in their description or question text

Combined NAMPT-Alectinib Targeting of SASP-Complement Cascade

Score: 0.549 · neuroinflammation · 2026-04-16

## Mechanistic Overview Combined NAMPT-Alectinib Targeting of SASP-Complement Cascade starts from the claim that modulat

NAD+ Salvage Pathway Optimization

Score: 0.455 · neurodegeneration · 2026-04-27

Target NAMPT enhancement or CD38 inhibition to restore NAD+ levels and sirtuin function in APOE4 microglia, addressing f

NAMPT

Understanding Entity Pages

Summary

Wiki Pages (2)

NAMPT Gene

NAMPT Protein

Pathway Diagram

Outgoing (404)

Incoming (178)

Targeting Hypotheses (7)

Mentioning Analyses (8)

What mechanisms drive the self-amplifying vicious cycle linking oxidative stress

Do β-amyloid plaques and neurofibrillary tangles cause or result from cholinergi

Which specific metabolic pathways in APOE4+ microglia are most therapeutically t

Senescent cell clearance as neurodegeneration therapy

Which metabolic biomarkers can distinguish therapeutic response from disease pro

Metabolic reprogramming in neurodegenerative disease

Sleep disruption as cause and consequence of neurodegeneration

Senolytic therapy for age-related neurodegeneration

Experiments (5)

Related Papers (7)

Debates (16)

Extended debate: Metabolic Reprogramming to Reverse Senescence

Hypothesis debate: Metabolic Reprogramming to Reverse Senescence

Hypothesis debate: SASP-Mediated Complement Cascade Amplification

Hypothesis debate: SASP Modulation Rather Than Cell Elimination

Hypothesis debate: Metabolic Reprogramming to Reverse Senescence

Hypothesis debate: Metabolic Reprogramming to Reverse Senescence

What mechanisms drive the self-amplifying vicious cycle linking oxidative stress

Should metabolic reprogramming via SIRT1/NAD+/PGC-1alpha axis be prioritized to

The abstract explicitly questions whether AD's hallmark pathologies induce choli

Investigate the therapeutic potential of clearing senescent cells (senolytics) t

Related Research

Combined NAMPT-Alectinib Targeting of SASP-Complement Cascade

NAD+ Salvage Pathway Optimization